In this edition:
FIRST: dostarlimab + niraparib in advanced ovarian cancer
ROSELLA: relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer
TRUST: radical upfront surgical therapy in advanced ovarian cancer
OUTBACK: patient-reported outcomes in locally advanced cervical cancer
FRα expression in real-world ovarian cancers
PAOLA-1: exploratory analysis of GIS scores
Third-line & later treatments in PSROC after PARPi exposure
Pembrolizumab + lenvatinib in recurrent/persistent CCOC
Letrozole, abemaciclib & metformin in recurrent ER-positive endometrial cancer
A novel selective CDK2 inhibitor in advanced platinum-resistant ovarian cancer
Please login below to download this issue (PDF)